{"id":"https://openalex.org/W2318705335","doi":"https://doi.org/10.1158/1535-7163.targ-13-a37","title":"Abstract A37: Translational biomarkers for cancer drug response: Cell line panel derived drug response signature predicts patients\u2019 survival in a lung cancer clinic trial.","display_name":"Abstract A37: Translational biomarkers for cancer drug response: Cell line panel derived drug response signature predicts patients\u2019 survival in a lung cancer clinic trial.","alternate_titles":[],"publication_year":2013,"publication_date":"2013-11-01","ids":{"openalex":"https://openalex.org/W2318705335","doi":"https://doi.org/10.1158/1535-7163.targ-13-a37","mag":"2318705335"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-13-a37","doi":"https://doi.org/10.1158/1535-7163.targ-13-a37","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-13-a37","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2318705335"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100379778","display_name":"Bin Li","orcid":"https://orcid.org/0000-0002-8979-610X","observed_orcids":["https://orcid.org/0000-0002-8979-610X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bin Li","raw_affiliation_strings":["1Translational Medicine, Takeda Pharmaceutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Translational Medicine, Takeda Pharmaceutics, Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103036440","display_name":"Hyunjin Shin","orcid":"https://orcid.org/0009-0007-6819-4592","observed_orcids":["https://orcid.org/0009-0007-6819-4592"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hyunjin Shin","raw_affiliation_strings":["1Translational Medicine, Takeda Pharmaceutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Translational Medicine, Takeda Pharmaceutics, Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001616659","display_name":"Georgy Gulbekyan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I68384125","display_name":"Thomson Reuters (United States)","ror":"https://ror.org/00m7gt169","country_code":"US","type":"company","lineage":["https://openalex.org/I68384125"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Georgy Gulbekyan","raw_affiliation_strings":["2IP & Science, Thomson Reuters, Carlsbad, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2IP & Science, Thomson Reuters, Carlsbad, CA","institution_ids":["https://openalex.org/I68384125"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073820276","display_name":"Olga Pustovalova","orcid":"https://orcid.org/0000-0002-6908-6688","observed_orcids":["https://orcid.org/0000-0002-6908-6688"]},"institutions":[{"id":"https://openalex.org/I68384125","display_name":"Thomson Reuters (United States)","ror":"https://ror.org/00m7gt169","country_code":"US","type":"company","lineage":["https://openalex.org/I68384125"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olga Pustovalova","raw_affiliation_strings":["2IP & Science, Thomson Reuters, Carlsbad, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2IP & Science, Thomson Reuters, Carlsbad, CA","institution_ids":["https://openalex.org/I68384125"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070287780","display_name":"Yuri Nikolsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I68384125","display_name":"Thomson Reuters (United States)","ror":"https://ror.org/00m7gt169","country_code":"US","type":"company","lineage":["https://openalex.org/I68384125"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yuri Nikolsky","raw_affiliation_strings":["2IP & Science, Thomson Reuters, Carlsbad, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2IP & Science, Thomson Reuters, Carlsbad, CA","institution_ids":["https://openalex.org/I68384125"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010067099","display_name":"Andrew J. Hope","orcid":"https://orcid.org/0000-0001-6793-2863","observed_orcids":["https://orcid.org/0000-0001-6793-2863"]},"institutions":[{"id":"https://openalex.org/I68384125","display_name":"Thomson Reuters (United States)","ror":"https://ror.org/00m7gt169","country_code":"US","type":"company","lineage":["https://openalex.org/I68384125"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Hope","raw_affiliation_strings":["2IP & Science, Thomson Reuters, Carlsbad, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2IP & Science, Thomson Reuters, Carlsbad, CA","institution_ids":["https://openalex.org/I68384125"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028186044","display_name":"Marina Bessarabova","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I68384125","display_name":"Thomson Reuters (United States)","ror":"https://ror.org/00m7gt169","country_code":"US","type":"company","lineage":["https://openalex.org/I68384125"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marina Bessarabova","raw_affiliation_strings":["2IP & Science, Thomson Reuters, Carlsbad, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2IP & Science, Thomson Reuters, Carlsbad, CA","institution_ids":["https://openalex.org/I68384125"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042664663","display_name":"Matthew C. Schu","orcid":"https://orcid.org/0000-0003-0630-1026","observed_orcids":["https://orcid.org/0000-0003-0630-1026"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew Schu","raw_affiliation_strings":["1Translational Medicine, Takeda Pharmaceutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Translational Medicine, Takeda Pharmaceutics, Cambridge, MA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016389673","display_name":"William L. Trepicchio","orcid":"https://orcid.org/0000-0002-9989-0183","observed_orcids":["https://orcid.org/0000-0002-9989-0183"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Trepicchio","raw_affiliation_strings":["1Translational Medicine, Takeda Pharmaceutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Translational Medicine, Takeda Pharmaceutics, Cambridge, MA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"12","issue":"11_Supplement","first_page":"A37","last_page":"A37"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.6327999830245972,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.6327999830245972,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.1808999925851822,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11287","display_name":"Cancer Genomics and Diagnostics","score":0.03830000013113022,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/translational-biomarkers","display_name":"translational biomarkers","score":0.8669999837875366},{"id":"https://openalex.org/keywords/drug-response-prediction","display_name":"drug response prediction","score":0.6159999966621399},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.8690000176429749},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9160000085830688},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":1.0},{"id":"https://openalex.org/keywords/cell-line-panel","display_name":"cell line panel","score":0.8190000057220459},{"id":"https://openalex.org/keywords/partial-least-squares-regression","display_name":"partial least squares regression","score":0.8500000238418579},{"id":"https://openalex.org/keywords/predictive-gene-signature","display_name":"predictive gene signature","score":0.5759999752044678},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7620000243186951},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.5099999904632568},{"id":"https://openalex.org/keywords/patient-stratification","display_name":"patient stratification","score":0.5950000286102295},{"id":"https://openalex.org/keywords/ic50","display_name":"IC50","score":0.5400000214576721},{"id":"https://openalex.org/keywords/targeted-therapy-response","display_name":"targeted therapy response","score":0.39800000190734863},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.6629999876022339}],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.9194462299346924},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.7917536497116089},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5159474015235901},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4853993356227875},{"id":"https://openalex.org/C170734499","wikidata":"https://www.wikidata.org/wiki/Q1152227","display_name":"Pharmacogenomics","level":2,"score":0.42964810132980347},{"id":"https://openalex.org/C2779733811","wikidata":"https://www.wikidata.org/wiki/Q5531562","display_name":"Gene signature","level":4,"score":0.429115355014801},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3830089569091797},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.37893638014793396},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.3549547791481018},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.34034496545791626},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3077632188796997},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.28183627128601074},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.19960647821426392},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.14507335424423218},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.11755985021591187},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.1121968924999237},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.09238451719284058},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-13-a37","doi":"https://doi.org/10.1158/1535-7163.targ-13-a37","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-13-a37","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1224843282","https://openalex.org/W2057752080","https://openalex.org/W2278505709","https://openalex.org/W2810789199","https://openalex.org/W2018663224","https://openalex.org/W1998361774","https://openalex.org/W2014385281","https://openalex.org/W2030953449","https://openalex.org/W2906692713"],"abstract_inverted_index":{"Abstract":[0],"Discovery":[1],"of":[2,90,150,203,220,225,232,282,308,338,361,412,469],"candidate":[3],"drug":[4,49,168,408,448,454],"sensitivity":[5,50],"predictive":[6,269,314,372,411],"genomic":[7],"models":[8,21,51,270,278,289,410],"using":[9,40,66,147,196,311],"pre-clinical":[10],"data":[11,46,69,96,204],"would":[12],"significantly":[13],"advance":[14],"the":[15,72,82,162,176,182,217,233,244,260,265,293,298,312,320,324,342,365,370,390,470],"ability":[16],"to":[17,47,102,123,132,212,242,255,292,316,332,375,406,415],"timely":[18],"validate":[19],"such":[20],"in":[22,41,71,259,396,460],"clinical":[23,74],"trials":[24],"and":[25,77,92,156,179,238,276,284,287,385,476],"utilize":[26],"them":[27],"for":[28,32,52,81,323,381,446],"selecting":[29],"appropriate":[30],"treatments":[31],"patients.":[33],"Here":[34],"we":[35],"report":[36],"a":[37,141,208,336,346,350,355,359,461],"case":[38,83,392],"study":[39,84,393],"vitro":[42,397],"cell":[43,115,125,142,266,398],"line":[44,116,267,399,451],"viability":[45,400],"build":[48],"Erlotinib":[53,76,133,151,275,313,371],"or":[54,130,134,152],"Sorafenib.":[55],"Each":[56],"individual":[57],"model":[58,165,192,299,315,344,373],"was":[59,121,145,173,194,253,328],"subsequently":[60],"tested":[61],"on":[62,167,271],"corresponding":[63,294],"treatment":[64,103,383],"arms":[65],"patient":[67,100,326],"response":[68,414,455],"generated":[70,160],"BATTLE":[73,109,272,318],"trial.":[75,465],"Sorafenib":[78,135,277,343,382],"were":[79,128,159,367],"selected":[80],"as":[85,175,181],"they":[86],"have":[87],"clear":[88],"mechanism":[89,307],"actions,":[91],"publicly":[93],"available":[94,105],"molecular":[95],"sets":[97],"coupled":[98],"with":[99,335,349,358],"outcome":[101],"are":[104,290],"(the":[106],"MD":[107],"Anderson":[108],"clinic":[110,464],"trial).":[111],"A":[112,185],"240":[113],"tumor":[114],"panel":[117,452],"(Oncopanel":[118],"from":[119],"Eurofins)":[120],"used":[122,174,405],"identify":[124],"lines":[126],"that":[127,395],"sensitive":[129,409],"resistant":[131],"treatment,":[136],"respectively.":[137],"For":[138,164],"each":[139,304],"drug,":[140],"proliferation":[143],"assay":[144],"conducted":[146],"10":[148],"doses":[149],"Sorafinib":[153],"(3-fold":[154],"dilution)":[155],"IC50":[157,180],"values":[158],"across":[161,216],"panel.":[163],"building":[166],"sensitivity,":[169],"baseline":[170],"gene":[171,236],"expression":[172],"independent":[177],"variable":[178],"dependent":[183],"variable.":[184],"6-step":[186],"Partial":[187],"Least":[188],"Squares":[189],"Regression":[190],"(PLSR)":[191],"workflow":[193],"developed":[195],"OncoPanel":[197],"data,":[198,274],"which":[199],"includes":[200],"multiple":[201],"steps":[202],"reduction,":[205],"feature":[206],"selection,":[207],"special":[209],"splitting":[210],"strategy":[211],"capture":[213,256],"consistent":[214],"features":[215],"dataset,":[218],"selection":[219,231],"least-overlapping":[221],"top":[222],"models,":[223],"calculation":[224],"consensus":[226,257],"genes":[227,302],"weights":[228],"followed":[229],"by":[230],"core":[234],"signature":[235,301,456],"set,":[237],"ontology":[239],"enrichment":[240],"filtering":[241],"obtain":[243],"pathway-based":[245],"PLSR":[246],"model.":[247],"This":[248],"specially":[249],"designed":[250],"modeling":[251],"approach":[252],"aimed":[254],"information":[258],"training":[261],"dataset.":[262],"When":[263,310],"testing":[264],"derived":[268,300,453],"patients\u2019":[273,413,458],"achieved":[279],"overall":[280],"accuracy":[281],"84%":[283],"79%":[285],"respectively,":[286],"these":[288],"specific":[291],"drugs.":[295],"In":[296],"addition,":[297],"reflect":[303],"drug's":[305],"known":[306],"action.":[309],"stratify":[317],"patients,":[319],"median":[321],"PFS":[322,337,353,360],"Erlotinib-sensitive":[325],"group":[327,348,357],"3.84":[329],"month":[330,352],"compared":[331],"Erlotinib-resistant":[333],"patients":[334],"1.84":[339],"month.":[340],"Similarly,":[341],"identified":[345],"marker-sensitive":[347,377],"4.53":[351],"vs.":[354,378],"marker-resistant":[356],"1.87":[362],"months.":[363],"Importantly,":[364],"signatures":[366],"drug-specific":[368],"-":[369],"failed":[374],"separate":[376],"marker-insensitive":[379],"groups":[380],"arm":[384],"vise":[386],"versa.":[387],"Taking":[388],"together,":[389],"current":[391],"demonstrates":[394],"screening":[401],"studies":[402],"can":[403],"be":[404],"derive":[407],"treatment.":[416],"Citation":[417,424],"Information:":[418],"Mol":[419,487],"Cancer":[420,477,488],"Ther":[421,489],"2013;12(11":[422,490],"Suppl):A37.":[423],"Format:":[425],"Bin":[426],"Li,":[427],"Hyunjin":[428],"Shin,":[429],"Georgy":[430],"Gulbekyan,":[431],"Olga":[432],"Pustovalova,":[433],"Yuri":[434],"Nikolsky,":[435],"Andrew":[436],"Hope,":[437],"Marina":[438],"Bessarabova,":[439],"Matthew":[440],"Schu,":[441],"William":[442],"Trepicchio.":[443],"Translational":[444],"biomarkers":[445],"cancer":[447,463],"response:":[449],"Cell":[450],"predicts":[457],"survival":[459],"lung":[462],"[abstract].":[466],"In:":[467],"Proceedings":[468],"AACR-NCI-EORTC":[471],"International":[472],"Conference:":[473],"Molecular":[474],"Targets":[475],"Therapeutics;":[478],"2013":[479],"Oct":[480],"19-23;":[481],"Boston,":[482],"MA.":[483],"Philadelphia":[484],"(PA):":[485],"AACR;":[486],"Suppl):Abstract":[491],"nr":[492],"A37.":[493]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2318705335","counts_by_year":[],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2016-06-24T00:00:00"}
